Novo Nordisk shares tumble as weight-loss drug trial data disappoints

Obesity drug CagriSema misses goal of 25% body weight reduction

Topics

Novo Nordisk’s drug stumble leaves it suddenly much slimmer

Market will never be winner takes all given that different patients will have different requirements
Financial Times - 2h
Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial results that missed expectations.
CNBC - 2h
Ozempic parent’s stock having worst day since the 1980s as new weight-loss drug disappoints

Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.
MarketWatch - 3h
Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.

In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.
The New York Times - 1d
Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition

A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, a new Doximity report finds.
CNBC - 2d
Novo Nordisk to invest $1.2 billion in new plant in Denmark

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday. "Designed to be ...
Yahoo Sports - 4d
Eli Lilly's obesity drug beats rival in head-to-head trial — where Cramer sees shares going next

New trial data has cemented Club holding Eli Lilly's pole position in the highly competitive weight loss drug race.
CNBC - Dec. 4
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
CNBC - Dec. 4
Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Terns Pharmaceuticals Inc.’s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an early-stage trial of a treatment for chronic myeloid leukemia.
MarketWatch - Dec. 3

Novo Nordisk shares tumble as weight-loss drug trial data disappoints

Topics

Related

Novo Nordisk’s drug stumble leaves it suddenly much slimmer

Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps

Ozempic parent’s stock having worst day since the 1980s as new weight-loss drug disappoints

Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.

Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition

Novo Nordisk to invest $1.2 billion in new plant in Denmark

Eli Lilly's obesity drug beats rival in head-to-head trial — where Cramer sees shares going next

Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

More from Financial Times

Trump wants 5% Nato defence spending target, Europe told

Trump tells EU to buy US oil and gas or face tariffs

Peter Mandelson named as UK’s Washington ambassador

The last days of Assad

There is a way out of the doom loop for Labour